Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer.

With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.

Therapeutics

Pharmaceutical

Life Sciences

Panavance Therapeutics Inc.

Greg Bosch

Thomas P. Hess

Tom Hess

José Iglesias

Ben Steinmetz

The Leadership Team at Panavance Therapeutics Inc. is responsible for steering the company’s strategic direction, overseeing clinical and commercial operations, ensuring financial stability, and fostering key academic and industry partnerships to advance the development and global distribution of the novel oncology therapeutic, GP-2250.

Leadership Team

Scientific and Research Team

Leadership Team

About

Team members

Other teams at Panavance Therapeutics Inc.

Scientific and Research Team